CA2061567C - Use of hyaluronic acid to repair ischemia reperfusion damage - Google Patents
Use of hyaluronic acid to repair ischemia reperfusion damageInfo
- Publication number
- CA2061567C CA2061567C CA002061567A CA2061567A CA2061567C CA 2061567 C CA2061567 C CA 2061567C CA 002061567 A CA002061567 A CA 002061567A CA 2061567 A CA2061567 A CA 2061567A CA 2061567 C CA2061567 C CA 2061567C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- hyaluronic acid
- tissue
- treating
- ischemia damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
Abstract
A pharmaceutical composition comprising an effective non-toxic amount of hyaluronic acid (HA) and or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and units of HA in association with a suitable diluent or pharmaceutically acceptable carrier for use in treating ischemia damage in tissue.
Description
. IEI,D OF INVENTION 2 0 617 6 7 This invention relates to repair through reperfusion of ischemia damage to tissue particularly internal organs and most particularly to the liver, heart, and kidneys and formulations for use to repair through S reperfusion such ischemia damage and me~ods of treating such conditions.
BACKGROIJND OF THE INVENTION
United States Patent 4,801,619 relates to hyaluronic acid administered intra-ar~icularly having a molecular weight of about 3 X 106 dalton more, which is prolle to decrease the proteoglycan content of synovial 10 fluid to almost normal levels. According to this paten~, this indicates a positive effect on the proteoglycan metabolism of a joint. According to the Patent this is applicable both to infl~mm~tory conditions and to degeneration caused by tre~tm~n~ with symptomatics, such as corticosteroid ~r~arations. It is thus clear that a sufficiently high molecular weight of the hyaluronic acid is l S alleged to counteract side ef~ects that might be caused by corticosteroids or other symptomatics prodwcing similar effects. When corticosteroids are applied, the amount of hyaluronic acid in the synovial cavity will according to the PatPnt increase substS.nti:-lly and according to the inventors their hyaluronic acid preparations have a very positive effect on such clinical 2 0 symptoms as pain, swelling and larneness.
The patent states that the objectives of the invention are attained by intra-articular a~lmini~tration of an effective amount of hyaluronic acid with a mean molecular weight exceeding 3 X 106 dalton, preferably exceeding 4 X 106 dalton; usually the molecular weight will not exceed 7 X 106 dalton.
2 5 The dosage of hy~luronic acid a~lmini~tered is stated to be preferably within the range of Smg-80kng. llhe annount of solution given at each ~ mini.~tration is generally less than 60 ml, e.g. less that 20 ml, of an aqueous solution of the acid or its salt. It is convenient to a(lmini.~ter the acid dissolved in water ~<2%
w/w, buffered to phys;ological pH), for instance in ~e form of a water-3 0 soluble sodium salt. The exact amount will depend on $he particular joint tobe treated.
~061~67 .
;- The Merck Index specifies that hyaluronic acid has a molecular weight within the range pf 50,000 to 8 X 106 depending on source, methods of preparation and methods of determination. The Merck Publication teaches hyaluronic acid as a surgical aid (oph~almological).
S United States Patent 4,808,576 purports to teach that hyaluronic acid, an agent well known to reduce ~e sequelae of trauma in m~mm~ n joint tissue when applied directly to the tr~llm~ti7ecl tissue, will be carried to such tr~um~ti7e-1 tissue by ~e m~mm~l's natural processes if applied at a site remote from the traumatized tissue. Thus hyaluronic acid in any therapeutically acceptable form can, according to the Patent, be ~mini~tered by the typical remote routes including intravenous, intramuscular, subc--t~neous and topical~
This, the patent alleges, makes the lltili7~tion of hyaluronic acid much more convenient and attractive. For instance the treatment of arthritis 1~ in horse or human joints with hyaluronic acid according to the patent no longer requires more difficult intra articular injections.
United States Patent 4,725,585 relates to a method of enhancing or regulating the host defence of a m:~mm~l, said method comprising ~lmini.~tering to a m~mm~l a therapeutically effective amount of hyaluronic 2 0 acid.
At column 1 lines 43 - 46, the patent provides that the invention was based on the unexpected discovery that a~lmini~tration of hyaluronic acid to msmm~ results in a considerable increase in the defence~
We have now discovered that hyaluronic acid and its salts and other forms are useful in repairin~ ischemia reperfusion damage in tissue particularly internal organs and most particularly ~he liver~
SUMMARY OF THE INVENTION
According to one aspec~ of the invention, a formulation for ?~imini~tration to a m~mm~l is provided comprising an amount of hyaluronic 3 0 acid and or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and sub units of hyaluronic acid e~fective to prevent or repair ischemia reperfusion damage in tissue particularly intemal organs for example the liver, together with a pharmaceutical carrier.
The hyaluronic acid in a carrier may be administered S intravenously, by infusion or any other suitable method and may be aflmini~tered up ~o about 7gm per 70 kg person per day. YVhile reduced amounts of hyaluronic acid may be delivered in dle carrier it is preferable tha~the least amount of hyaluronic acid be in the range of about 300mg/70kg person per day.
According to another aspect of the invention, a method of repairing ischemia reperfusion damage in tissue, particularly internal organs, and more particularly the liver, is provided comprising af1mini.~tering to the m~mm~l a therapeutically effective amoun~ of hyaluronic acid and or salts thereof and/or homologues, analogues, derivatives, complexes, esters, l S fragments and sub units of hyaluronic acid in a suitable carrier. Because hyaluronic acid targets the damaged tissue and ~acilitates its own penetration through the tissue at the si$e to be treated through the cell membranes into theindividual cells to be treated, it rapidly arrives at the site after introduction, for example, by intravenous methods and repairs the ischemia reperfusion 2 0 damage in the tissue, for example the liver, or prevents or minimi7es such damage (as for example in transplants such as the liver, heart, lungs, and kidneys).
The formulation can be a(lmini~tered among other methods, intravenously, intra-arterially, intraperitoneally, intrapleurally, transdermally, 2 5 on the skin, or by direct injection (for example into the liver).
One form of hyaluronic acid and/or salts thereof (for example sodium salt) and homologues, analogues, derivatives, complexes, esters, fragments and sub units of hyaluronic acid, preferably hyaluronic acid and salts and thereof suitable for use with Applicant's invention is a fraction 3 0 suppled by Hyal Pharmaceuticals Limited. One such fraction is a lS ml vial of - 4 - 20~67 Sodium hyaluronate 20mg/ml (300mg/vial - Lot 2F3). The sodium hyaluronate fraction is a 2% solution with a mean average molecular weight of about 225,000. The fraction also contains water q.s. which is triple distilled and sterile in accordance with the U.S.P. for injection formulations.
S The vials of hyaluronic acid and/or salts thereof may be carried in Type 1 borosilicate g vial closed by a bu~yl stopper which does not react with the contP.nt.~ of ~e vial.
The fraction of hyaluronic acid and/or salts thereof (for example sodium salt) and homologues, analogues, deriva~ives, complexes, esters, fragment~ and sub units of hyaluronic acid, pre~erably hyaluronic acid and salts and thereof may comprise hyaluronic acid and/or salts thereof having the following characteristics:
a purified, subst;-nti~lly pyrogen-free fraction of hyaluronic acid obtained from a natural source having at least one characteristic selected from the group consisting of ~e following:
(i) a molecular weight widlin the range of 150,000 -700,000;
(ii) less than about 1.25% sulphated mucopolysaccharides on a total weight basis;
(iii) less than about 0.6% protein on a total weight basis;
2 0 (iv) less than about 150 ppm iron on a total weight basis;
(v) less than about 15 ppm lead on a total weight basis;
(vi) less ~an 0.0025% glucos~mine;
(vii) less than 0.025% glucuronic acid;
~viii) less than 0.025% N-acetylglucosamine;
2 S (ix) less ~an 0.0025% amino acids;
(x) a IJV extinction coefficient at 257 nm of less than about 0.275;
(xi) a UV extinction coefficient at 280nm of less than about 0.25; and 3 0 (xii) a pH within the range of 7.3 - 7.9.
~ 5 ~ 20~1~67 Preferably the hyaluronic acid is mixed with water and the fraction of hyaluronic acid fraction has a mean average molecular weight within the range of 150,000 - 225,000. More pre~erably the fraction of hyaluronic acid comprises at least one characteristic selected from the group S consisting of the following characteristics:
(i) less than about 1% sulphated mueopolysaccharides on a total weight basis;
(ii) less than about 0.4% protein on a total weight basis;
(iii) less ~an about 100 ppm iron on a total weight basis;
l 0 (iv) less ~an about 10 ppm lead on a total weight basis;
(v) less than 0.00166% glucosamine;
(vi) less than 0.0166% glucuronic acid;
(vii) less than 0.0166% N-acetylglucosamine;
(viii) less than 0.00166% amino acids;
(ix) a UV extinction coefficient at 257 nm of less than about 0.23;
(x) a UV extinction coe~ficient at 280 nm of less than about 0.19; and (xi) a pH wi~in the range of 7.5 - 7.7.
2 0 Other forms of hyaluronic acid and/or its salts, and homologues, derivatives, complexes, esters, fragments and sub UllitS hyaluronic acid may be chosen from other suppliers, for example those described in the prior ar~
documents previously referred to. In addition Applicants have successfully employed sodium hyaluronate produced and supplied by Lii~eCore~
Biomedical, Inc. having d:~e following specifications Characteristics Specification Appearance White to cream colored particles Odor No perceptible Odor -6- 2~61~67 Viscosity Average Molecular Weight < 750,000 Daltons UV/Vis Scan, 190-820nm Matches reference scan OD, 260nm < Q.25 OD units S Hyaluronidase Sensitivity Positive response IR Scan Matches reference pH, 10mg/g solution 6.2 - 7.8 Water 8% maximum Protein <û.3 mcg/mg NaHy Acetate < 10.0 mcg/mg NaHy Heavy Metals~ Maximum ppm As Cd Cr Co Cu Fe Pb Hg Ni 2.0 5.0 5.0 10.0 10.0 25.0 10.0 10.0 5.0 Microbial Bioburden None Obselved Endotoxin < 0.07 EU/mg NaHy Biological Safety Testing Passes Rabbit Ocular Toxicity Test The following references teach hyaluronic acid, sources thereof and processes of the m~n~lf~cture and recovery dlereof.
United States Patent 4,141,973 teaches hyaluronic acid fractions (including sodium salts) having:
"(a) an average molecular weight greater than about 750,000, preferably greater than about 1,200,000 - that is, a limiting viscosity number greater than about 1400 2 5 cm3/g., and preferably greater than about 2000 cm3/g.;
(b) a protein content of less than 0.5% by weight;
(c) ultraviolet light absorbance of a 1% solution of sodium hyaluronate of less than 3.0 at 257 nanometers wavelength and less than 2.0 at 280 nanometers wavelength;
2061~67 (d) a kinematic viscosity of a 1% solution of sodium hyaluronate in physiological buf~er greater than about 10 centistokes, preferably greater than 10,000 centistokes;
(e) a molar optical rotation o-f a 0.1 - 0.2% sodium S hyaluronate solution in physiolocal buffer of less than -11 X 103 degree - cm2/mole (of disaccharide) measure at 220 nanometers;
(f) no significant cellular infiltration of the vitreaous and anterior chamber, no flare in the aqueous humor, no haze or flare in the vitreous and no pathological changes to ~he cornea, lens, iris, retina, and choroid of the owl monkey eye when one milliliter of a 1% solution of sodium hyaluronate dissolved in physiological buffer is implanted in the vitreous replacing approxima~ely one-half the 1 5 exi.~tin~. liquid vitreous, said HUA being;
(g) sterile and pyrogen free and (h) non-antigenic."
C~nArli~n Letters Patent 1,2059031 (which re~ers to United States Patent 4,141,973 as prior art) re~ers to hyaluronic acid fractions having 2 0 average molecular weights of from 50,000 to 100,000; 250,000 to 350,000;
and S00,000 to 730,000 and (li.~cllsses processes of ~eir m~n~lf~ctllre.
According to yet another aspect of the invention, Alanine Aminotransferase production in damaged tissue, for example the liver is reduced by the administration of, for example hyaluronic acid and/or salts 2 5 thereof in association with a suitable diluent or pharmaceutically acceptable carrier.
The following examples are offered to illustrate Applicants' invention but in no way limit the scope of ~he invention.
Applicants believe ~at Drug uptake is affécted by cellular damage 3 0 associated with tissue malperfusion. The glycosaminoglycan, Hyaluronic Acid 2 ~ 6~ 7 (HA) has been shown to a~fect eellular membrane activity. To assess its potential effec~ upon drug uptake we did the -following studies. We studied ~e effect of HA on tritiated S-Fluorouracil (3H-s-FU) uptake by acute and chronic malperfused rat liver tissue using 2 models.
S Example 1: Ischemia~eperfusion Two groups of rats (A,B) were subjected to 30 minute liver ischemia followed by a period of reperfusion. Two sham groups (C, D) served as controls. Two additional groups (E, F) unde~went a 'once-through' liver perfusion in order to quantita~e tissue bound drug. All groups received intravenous 3H-5-Flourouracil (a radioactive tracer) (3H-s-FU) at ~e end of the reperfusion pe~iod. Groups A, C, and F received in addition intravenous (HA) Hyaluronic Acid (15 mg/kg).
Samples of liver tissue were processed and counted for radioactivity. The groups treated widl HA showed a significantly higher (10%, l 5 p~0.05 ANOVA) uptake of 3H-s-Fu than in ~e untreated groups. Following 'once through' perfusion the dif~erence between the groups persists.
Exam~le 2: Liver Tumour (See Figure 1) Two groups of rats with liver-implanted m~mm~ry carcinoma received intravenous 3H-s-FU. One of the groups received intravenous HA as 2 0 well. Samples of tumour tissue were processed and coun$ed for radioactivity.
The uptake 3H-s-FlJ by tumour tissue was higher (40%, p~0.05 ANOVA) in the HA treated group compared to the untreated group.
The results in examples 1 and 2 teach that HA is involved in the observed enhancement of 3H-s-FU uptake by ischemi~treperfused rat liver and 2 5 by rat liver tumour. It has been previously suggested that the tissue injury or neoplasia may alter local HA production. Applicants have now found that e~ogenously given HA preferentially targets such tissues. The following data is offered.
2~6~7 ISCHEMIA ISC~EMLA +HA
mean sem mean sem 42952 g40 48277 871 44261 776 41q31 1131 44692 648 ~6140 863 42727 32~ 43189 950 The following additional data is also offered.
SUM SOUARF,S DE!GFRE~EDOM MEANSOUARE
2 0 TREATMENT 3.81E+07 1 3.81E~07 ERROR 7.40E+07 16 4622828 TOTAL 1.12EtO8 F-TEiST RATIO = 8.23240S
SIGNIFICANCE = 0.0111 TREATMENT MEAN ERROR OBSERVAllONS
VAR - 1 42483.S7 568.8718 9 3 5 VAR - 2 45391.78 838.8565 9 TREATMENT MEAN DUNCAN'S MULTIPLE-RA~GE TEST
___ GROUP 1 42483.67 GROUP 2 45391.78 STANDARD ERROR OF TREATMENT MEANS = 716.6921 TREATMENT VS. IREATMENT Dl~RENCE SIG. 0.5 SIG .01 GROUP 1 GROUP 2 2908.109 ~ -TREATMENl' MEANS NEWMAN-KEULS' MULTIPLERANGE TEST
GROUP 1 42483.67 GROUP 2 45391.78 2061~67 STANDARD ER~OR OF TREATMENT MEANS = 716.6921 TREATMENT VS. TREATMENT DlFPEREiNCE SIG.05 SIG 0.1 S
GROUP 1 GROIJP 2 2908.109 ~ -TREATMENT MEAN DUNNElTS MULTIPLE-RANGETEST
GROUP 1 42483.67 GROUP 2 45391.78 STANDARD ERROR OF rFREATMENT MEANS = 1013.556 TREATMENT VS. ~EATMENT Dl~kRENCE SIG.05 SIG.01 GROUP I GROUP 2 2908.109 ~ -~2 5 TREATMENT MEAN LEAST SIGNIFICANT DIFPERENCE MULTIPLERANGE TE~T
____ GROUP 1 42483.67 GROUP 2 45391.78 STANDARD ERROR OF TREATMENl MEANS = 716.~921 3 5 TREATMENT VS. TREATMENT Dll~ NCE SIG .05 GROUP 1 GROUP 2 2908.109 *
4 0 Example 3 Alanine Aminotransferase (ALT) is an enzyme released by the liver when the liver is damaged or when experiencing ischemi~ The lower the level of released ALT, ~e lower the level of damage. Two groups of ra$s un~l ~Ivellt liver i.~çhemi~ by clamping off the hepatic artery to ~e liver for 30 4 5 minutes followed by a period of reperfusion. One group was given intravenously a control injection whereas the other group was given HA
(Sodium hyaluronate) intravenously. Bo~ groups were measured for Alanine Aminotransferase levels. The group which received HA demonstrated significantly lower levels of Alanine Aminotransferase enzyme in the blood 5 0 stream compared to the control groups.
2 ~ 7 ALT (Alnninc A ~ r ) r~ ~ irl T ' ' ' ~ ~ ' Rats (Blood S~eam).
Absolute value E~pressed as percentage of base1ine Group 1 rat# Bnseline 30' 72hrs Baseline 30' 72hrs S *~A 1 80 592 137 740 171 9 ~9 484 43 82û 73 mean 94.67 415.75 66.75 ~2 86.96 sed 16.26 54.46 23.46 94.44 28.67 Group 2 rat#
BACKGROIJND OF THE INVENTION
United States Patent 4,801,619 relates to hyaluronic acid administered intra-ar~icularly having a molecular weight of about 3 X 106 dalton more, which is prolle to decrease the proteoglycan content of synovial 10 fluid to almost normal levels. According to this paten~, this indicates a positive effect on the proteoglycan metabolism of a joint. According to the Patent this is applicable both to infl~mm~tory conditions and to degeneration caused by tre~tm~n~ with symptomatics, such as corticosteroid ~r~arations. It is thus clear that a sufficiently high molecular weight of the hyaluronic acid is l S alleged to counteract side ef~ects that might be caused by corticosteroids or other symptomatics prodwcing similar effects. When corticosteroids are applied, the amount of hyaluronic acid in the synovial cavity will according to the PatPnt increase substS.nti:-lly and according to the inventors their hyaluronic acid preparations have a very positive effect on such clinical 2 0 symptoms as pain, swelling and larneness.
The patent states that the objectives of the invention are attained by intra-articular a~lmini~tration of an effective amount of hyaluronic acid with a mean molecular weight exceeding 3 X 106 dalton, preferably exceeding 4 X 106 dalton; usually the molecular weight will not exceed 7 X 106 dalton.
2 5 The dosage of hy~luronic acid a~lmini~tered is stated to be preferably within the range of Smg-80kng. llhe annount of solution given at each ~ mini.~tration is generally less than 60 ml, e.g. less that 20 ml, of an aqueous solution of the acid or its salt. It is convenient to a(lmini.~ter the acid dissolved in water ~<2%
w/w, buffered to phys;ological pH), for instance in ~e form of a water-3 0 soluble sodium salt. The exact amount will depend on $he particular joint tobe treated.
~061~67 .
;- The Merck Index specifies that hyaluronic acid has a molecular weight within the range pf 50,000 to 8 X 106 depending on source, methods of preparation and methods of determination. The Merck Publication teaches hyaluronic acid as a surgical aid (oph~almological).
S United States Patent 4,808,576 purports to teach that hyaluronic acid, an agent well known to reduce ~e sequelae of trauma in m~mm~ n joint tissue when applied directly to the tr~llm~ti7ecl tissue, will be carried to such tr~um~ti7e-1 tissue by ~e m~mm~l's natural processes if applied at a site remote from the traumatized tissue. Thus hyaluronic acid in any therapeutically acceptable form can, according to the Patent, be ~mini~tered by the typical remote routes including intravenous, intramuscular, subc--t~neous and topical~
This, the patent alleges, makes the lltili7~tion of hyaluronic acid much more convenient and attractive. For instance the treatment of arthritis 1~ in horse or human joints with hyaluronic acid according to the patent no longer requires more difficult intra articular injections.
United States Patent 4,725,585 relates to a method of enhancing or regulating the host defence of a m:~mm~l, said method comprising ~lmini.~tering to a m~mm~l a therapeutically effective amount of hyaluronic 2 0 acid.
At column 1 lines 43 - 46, the patent provides that the invention was based on the unexpected discovery that a~lmini~tration of hyaluronic acid to msmm~ results in a considerable increase in the defence~
We have now discovered that hyaluronic acid and its salts and other forms are useful in repairin~ ischemia reperfusion damage in tissue particularly internal organs and most particularly ~he liver~
SUMMARY OF THE INVENTION
According to one aspec~ of the invention, a formulation for ?~imini~tration to a m~mm~l is provided comprising an amount of hyaluronic 3 0 acid and or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and sub units of hyaluronic acid e~fective to prevent or repair ischemia reperfusion damage in tissue particularly intemal organs for example the liver, together with a pharmaceutical carrier.
The hyaluronic acid in a carrier may be administered S intravenously, by infusion or any other suitable method and may be aflmini~tered up ~o about 7gm per 70 kg person per day. YVhile reduced amounts of hyaluronic acid may be delivered in dle carrier it is preferable tha~the least amount of hyaluronic acid be in the range of about 300mg/70kg person per day.
According to another aspect of the invention, a method of repairing ischemia reperfusion damage in tissue, particularly internal organs, and more particularly the liver, is provided comprising af1mini.~tering to the m~mm~l a therapeutically effective amoun~ of hyaluronic acid and or salts thereof and/or homologues, analogues, derivatives, complexes, esters, l S fragments and sub units of hyaluronic acid in a suitable carrier. Because hyaluronic acid targets the damaged tissue and ~acilitates its own penetration through the tissue at the si$e to be treated through the cell membranes into theindividual cells to be treated, it rapidly arrives at the site after introduction, for example, by intravenous methods and repairs the ischemia reperfusion 2 0 damage in the tissue, for example the liver, or prevents or minimi7es such damage (as for example in transplants such as the liver, heart, lungs, and kidneys).
The formulation can be a(lmini~tered among other methods, intravenously, intra-arterially, intraperitoneally, intrapleurally, transdermally, 2 5 on the skin, or by direct injection (for example into the liver).
One form of hyaluronic acid and/or salts thereof (for example sodium salt) and homologues, analogues, derivatives, complexes, esters, fragments and sub units of hyaluronic acid, preferably hyaluronic acid and salts and thereof suitable for use with Applicant's invention is a fraction 3 0 suppled by Hyal Pharmaceuticals Limited. One such fraction is a lS ml vial of - 4 - 20~67 Sodium hyaluronate 20mg/ml (300mg/vial - Lot 2F3). The sodium hyaluronate fraction is a 2% solution with a mean average molecular weight of about 225,000. The fraction also contains water q.s. which is triple distilled and sterile in accordance with the U.S.P. for injection formulations.
S The vials of hyaluronic acid and/or salts thereof may be carried in Type 1 borosilicate g vial closed by a bu~yl stopper which does not react with the contP.nt.~ of ~e vial.
The fraction of hyaluronic acid and/or salts thereof (for example sodium salt) and homologues, analogues, deriva~ives, complexes, esters, fragment~ and sub units of hyaluronic acid, pre~erably hyaluronic acid and salts and thereof may comprise hyaluronic acid and/or salts thereof having the following characteristics:
a purified, subst;-nti~lly pyrogen-free fraction of hyaluronic acid obtained from a natural source having at least one characteristic selected from the group consisting of ~e following:
(i) a molecular weight widlin the range of 150,000 -700,000;
(ii) less than about 1.25% sulphated mucopolysaccharides on a total weight basis;
(iii) less than about 0.6% protein on a total weight basis;
2 0 (iv) less than about 150 ppm iron on a total weight basis;
(v) less than about 15 ppm lead on a total weight basis;
(vi) less ~an 0.0025% glucos~mine;
(vii) less than 0.025% glucuronic acid;
~viii) less than 0.025% N-acetylglucosamine;
2 S (ix) less ~an 0.0025% amino acids;
(x) a IJV extinction coefficient at 257 nm of less than about 0.275;
(xi) a UV extinction coefficient at 280nm of less than about 0.25; and 3 0 (xii) a pH within the range of 7.3 - 7.9.
~ 5 ~ 20~1~67 Preferably the hyaluronic acid is mixed with water and the fraction of hyaluronic acid fraction has a mean average molecular weight within the range of 150,000 - 225,000. More pre~erably the fraction of hyaluronic acid comprises at least one characteristic selected from the group S consisting of the following characteristics:
(i) less than about 1% sulphated mueopolysaccharides on a total weight basis;
(ii) less than about 0.4% protein on a total weight basis;
(iii) less ~an about 100 ppm iron on a total weight basis;
l 0 (iv) less ~an about 10 ppm lead on a total weight basis;
(v) less than 0.00166% glucosamine;
(vi) less than 0.0166% glucuronic acid;
(vii) less than 0.0166% N-acetylglucosamine;
(viii) less than 0.00166% amino acids;
(ix) a UV extinction coefficient at 257 nm of less than about 0.23;
(x) a UV extinction coe~ficient at 280 nm of less than about 0.19; and (xi) a pH wi~in the range of 7.5 - 7.7.
2 0 Other forms of hyaluronic acid and/or its salts, and homologues, derivatives, complexes, esters, fragments and sub UllitS hyaluronic acid may be chosen from other suppliers, for example those described in the prior ar~
documents previously referred to. In addition Applicants have successfully employed sodium hyaluronate produced and supplied by Lii~eCore~
Biomedical, Inc. having d:~e following specifications Characteristics Specification Appearance White to cream colored particles Odor No perceptible Odor -6- 2~61~67 Viscosity Average Molecular Weight < 750,000 Daltons UV/Vis Scan, 190-820nm Matches reference scan OD, 260nm < Q.25 OD units S Hyaluronidase Sensitivity Positive response IR Scan Matches reference pH, 10mg/g solution 6.2 - 7.8 Water 8% maximum Protein <û.3 mcg/mg NaHy Acetate < 10.0 mcg/mg NaHy Heavy Metals~ Maximum ppm As Cd Cr Co Cu Fe Pb Hg Ni 2.0 5.0 5.0 10.0 10.0 25.0 10.0 10.0 5.0 Microbial Bioburden None Obselved Endotoxin < 0.07 EU/mg NaHy Biological Safety Testing Passes Rabbit Ocular Toxicity Test The following references teach hyaluronic acid, sources thereof and processes of the m~n~lf~cture and recovery dlereof.
United States Patent 4,141,973 teaches hyaluronic acid fractions (including sodium salts) having:
"(a) an average molecular weight greater than about 750,000, preferably greater than about 1,200,000 - that is, a limiting viscosity number greater than about 1400 2 5 cm3/g., and preferably greater than about 2000 cm3/g.;
(b) a protein content of less than 0.5% by weight;
(c) ultraviolet light absorbance of a 1% solution of sodium hyaluronate of less than 3.0 at 257 nanometers wavelength and less than 2.0 at 280 nanometers wavelength;
2061~67 (d) a kinematic viscosity of a 1% solution of sodium hyaluronate in physiological buf~er greater than about 10 centistokes, preferably greater than 10,000 centistokes;
(e) a molar optical rotation o-f a 0.1 - 0.2% sodium S hyaluronate solution in physiolocal buffer of less than -11 X 103 degree - cm2/mole (of disaccharide) measure at 220 nanometers;
(f) no significant cellular infiltration of the vitreaous and anterior chamber, no flare in the aqueous humor, no haze or flare in the vitreous and no pathological changes to ~he cornea, lens, iris, retina, and choroid of the owl monkey eye when one milliliter of a 1% solution of sodium hyaluronate dissolved in physiological buffer is implanted in the vitreous replacing approxima~ely one-half the 1 5 exi.~tin~. liquid vitreous, said HUA being;
(g) sterile and pyrogen free and (h) non-antigenic."
C~nArli~n Letters Patent 1,2059031 (which re~ers to United States Patent 4,141,973 as prior art) re~ers to hyaluronic acid fractions having 2 0 average molecular weights of from 50,000 to 100,000; 250,000 to 350,000;
and S00,000 to 730,000 and (li.~cllsses processes of ~eir m~n~lf~ctllre.
According to yet another aspect of the invention, Alanine Aminotransferase production in damaged tissue, for example the liver is reduced by the administration of, for example hyaluronic acid and/or salts 2 5 thereof in association with a suitable diluent or pharmaceutically acceptable carrier.
The following examples are offered to illustrate Applicants' invention but in no way limit the scope of ~he invention.
Applicants believe ~at Drug uptake is affécted by cellular damage 3 0 associated with tissue malperfusion. The glycosaminoglycan, Hyaluronic Acid 2 ~ 6~ 7 (HA) has been shown to a~fect eellular membrane activity. To assess its potential effec~ upon drug uptake we did the -following studies. We studied ~e effect of HA on tritiated S-Fluorouracil (3H-s-FU) uptake by acute and chronic malperfused rat liver tissue using 2 models.
S Example 1: Ischemia~eperfusion Two groups of rats (A,B) were subjected to 30 minute liver ischemia followed by a period of reperfusion. Two sham groups (C, D) served as controls. Two additional groups (E, F) unde~went a 'once-through' liver perfusion in order to quantita~e tissue bound drug. All groups received intravenous 3H-5-Flourouracil (a radioactive tracer) (3H-s-FU) at ~e end of the reperfusion pe~iod. Groups A, C, and F received in addition intravenous (HA) Hyaluronic Acid (15 mg/kg).
Samples of liver tissue were processed and counted for radioactivity. The groups treated widl HA showed a significantly higher (10%, l 5 p~0.05 ANOVA) uptake of 3H-s-Fu than in ~e untreated groups. Following 'once through' perfusion the dif~erence between the groups persists.
Exam~le 2: Liver Tumour (See Figure 1) Two groups of rats with liver-implanted m~mm~ry carcinoma received intravenous 3H-s-FU. One of the groups received intravenous HA as 2 0 well. Samples of tumour tissue were processed and coun$ed for radioactivity.
The uptake 3H-s-FlJ by tumour tissue was higher (40%, p~0.05 ANOVA) in the HA treated group compared to the untreated group.
The results in examples 1 and 2 teach that HA is involved in the observed enhancement of 3H-s-FU uptake by ischemi~treperfused rat liver and 2 5 by rat liver tumour. It has been previously suggested that the tissue injury or neoplasia may alter local HA production. Applicants have now found that e~ogenously given HA preferentially targets such tissues. The following data is offered.
2~6~7 ISCHEMIA ISC~EMLA +HA
mean sem mean sem 42952 g40 48277 871 44261 776 41q31 1131 44692 648 ~6140 863 42727 32~ 43189 950 The following additional data is also offered.
SUM SOUARF,S DE!GFRE~EDOM MEANSOUARE
2 0 TREATMENT 3.81E+07 1 3.81E~07 ERROR 7.40E+07 16 4622828 TOTAL 1.12EtO8 F-TEiST RATIO = 8.23240S
SIGNIFICANCE = 0.0111 TREATMENT MEAN ERROR OBSERVAllONS
VAR - 1 42483.S7 568.8718 9 3 5 VAR - 2 45391.78 838.8565 9 TREATMENT MEAN DUNCAN'S MULTIPLE-RA~GE TEST
___ GROUP 1 42483.67 GROUP 2 45391.78 STANDARD ERROR OF TREATMENT MEANS = 716.6921 TREATMENT VS. IREATMENT Dl~RENCE SIG. 0.5 SIG .01 GROUP 1 GROUP 2 2908.109 ~ -TREATMENl' MEANS NEWMAN-KEULS' MULTIPLERANGE TEST
GROUP 1 42483.67 GROUP 2 45391.78 2061~67 STANDARD ER~OR OF TREATMENT MEANS = 716.6921 TREATMENT VS. TREATMENT DlFPEREiNCE SIG.05 SIG 0.1 S
GROUP 1 GROIJP 2 2908.109 ~ -TREATMENT MEAN DUNNElTS MULTIPLE-RANGETEST
GROUP 1 42483.67 GROUP 2 45391.78 STANDARD ERROR OF rFREATMENT MEANS = 1013.556 TREATMENT VS. ~EATMENT Dl~kRENCE SIG.05 SIG.01 GROUP I GROUP 2 2908.109 ~ -~2 5 TREATMENT MEAN LEAST SIGNIFICANT DIFPERENCE MULTIPLERANGE TE~T
____ GROUP 1 42483.67 GROUP 2 45391.78 STANDARD ERROR OF TREATMENl MEANS = 716.~921 3 5 TREATMENT VS. TREATMENT Dll~ NCE SIG .05 GROUP 1 GROUP 2 2908.109 *
4 0 Example 3 Alanine Aminotransferase (ALT) is an enzyme released by the liver when the liver is damaged or when experiencing ischemi~ The lower the level of released ALT, ~e lower the level of damage. Two groups of ra$s un~l ~Ivellt liver i.~çhemi~ by clamping off the hepatic artery to ~e liver for 30 4 5 minutes followed by a period of reperfusion. One group was given intravenously a control injection whereas the other group was given HA
(Sodium hyaluronate) intravenously. Bo~ groups were measured for Alanine Aminotransferase levels. The group which received HA demonstrated significantly lower levels of Alanine Aminotransferase enzyme in the blood 5 0 stream compared to the control groups.
2 ~ 7 ALT (Alnninc A ~ r ) r~ ~ irl T ' ' ' ~ ~ ' Rats (Blood S~eam).
Absolute value E~pressed as percentage of base1ine Group 1 rat# Bnseline 30' 72hrs Baseline 30' 72hrs S *~A 1 80 592 137 740 171 9 ~9 484 43 82û 73 mean 94.67 415.75 66.75 ~2 86.96 sed 16.26 54.46 23.46 94.44 28.67 Group 2 rat#
menn 75 1086.6 82 ~ 97.80 2 0 sed 6.32 293.80 6.43 361.57 11.60 (SEE ~IGURE 2) - 12- 2061~7 Further ~est data is set out below:
(See Pigure 3) S Alanine Trans~erase Measurement in Ischemia Rats ~3Blood Stream~;
RAT# PREOP K)SIOP0' POSTOP30' POSTOP60' POP0'% POP30'~o POP60'%
1 67 ~9 1289 2030 342 192~ 3030 ~IEA~ 348.29 1182.71 1890.00 469.05 1611.05 2597.10 SEM 101.99 38.78 225.04 132.59 82.69 36~.79 2 0 8 98 478 1860 2940 488 1898 3~00 89 436 2930 3~00 4g0 3292 3820 11 105 590 1930 260~ 562 1838 2476 2 5 13 91 220 2170 3710 242 2385 4~77 14 98 343 1730 1940 3~0 1765 l9g0 ~IEA~ 83.5 362.00 2094.29 2941.43 382.14 2272.47 3192.73 SEM 59.69 160.71 249.85 53.71 215.06 318.48 M13AN COMPA~T'~ON
kL~ CO~rrROL
pos~p O' 348 362 pos~p 30' 1183 2094 pos~p 60' 1890 2941 pos~p 0' 469 382 4 0 pos~p 30' 1611 2272 pos~p 60' 2597 3193 As many changes can be made to ~e pre~erred embodiments of the invention wi~out departing from ~e scope of the invention; it is intended 4 5 that all material herein be treated as illustrative of the invention and not in a limitin~ sense.
(See Pigure 3) S Alanine Trans~erase Measurement in Ischemia Rats ~3Blood Stream~;
RAT# PREOP K)SIOP0' POSTOP30' POSTOP60' POP0'% POP30'~o POP60'%
1 67 ~9 1289 2030 342 192~ 3030 ~IEA~ 348.29 1182.71 1890.00 469.05 1611.05 2597.10 SEM 101.99 38.78 225.04 132.59 82.69 36~.79 2 0 8 98 478 1860 2940 488 1898 3~00 89 436 2930 3~00 4g0 3292 3820 11 105 590 1930 260~ 562 1838 2476 2 5 13 91 220 2170 3710 242 2385 4~77 14 98 343 1730 1940 3~0 1765 l9g0 ~IEA~ 83.5 362.00 2094.29 2941.43 382.14 2272.47 3192.73 SEM 59.69 160.71 249.85 53.71 215.06 318.48 M13AN COMPA~T'~ON
kL~ CO~rrROL
pos~p O' 348 362 pos~p 30' 1183 2094 pos~p 60' 1890 2941 pos~p 0' 469 382 4 0 pos~p 30' 1611 2272 pos~p 60' 2597 3193 As many changes can be made to ~e pre~erred embodiments of the invention wi~out departing from ~e scope of the invention; it is intended 4 5 that all material herein be treated as illustrative of the invention and not in a limitin~ sense.
Claims (35)
1. A pharmaceutical composition comprising an effective non-toxic amount of hyaluronic acid (HA) and or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and units of HA in association with a suitable diluent or pharmaceutically acceptable carrier for use in treating ischemia damage in tissue.
2. The pharmaceutical composition of claim 1 wherein the amount of hyaluronic acid is selected from hyaluronic acid and salts thereof.
3. The pharmaceutical composition of claim 2 for treating ischemia damage in tissue through reperfusion or the like.
4. The pharmaceutical composition of claim 2 for use in treating ischemia damage in internal organs.
5. The pharmaceutical composition of claim 2 for use in treating ischemia damage in the liver.
6. The pharmaceutical composition of claim 2 for use in treating ischemia damage in the kidneys.
7. The pharmaceutical composition of claim 2 for use in treating ischemia damage in the heart.
8. The pharmaceutical composition of claims 2 or 4 where said treatment comprises reperfusion.
9. The pharmaceutical composition of claims 5, 6 or 7 where said treatment comprises reperfusion.
10. The pharmaceutical composition of claim 2 for use in treating ischemia damage in tissue during transplantation.
11. The pharmaceutical composition of claim 2 for use in treating ischemia damage in tissue during transplantation of internal organs.
12. The pharmaceutical composition of claim 2 for use in treating ischemia damage in tissue during transplantation of the liver.
13. The pharmaceutical composition of claim 2 for use in treating ischemia damage in tissue during transplantation of the kidney or kidneys.
14. The pharmaceutical composition of claim 2 for use in treating ischemia damage in tissue during transplantation of the heart.
15. The pharmaceutical composition of claims 1-14 inclusive wherein the amount of hyaluronic acid or forms thereof is between about 300 mg to about 7 grams.
16. A formulation for reducing Alanine Aminotransferase enzyme production by a liver when damaged or is experiencing ischemia, said formulation comprising an effective non-toxic amount of hyaluronic acid and/or salts thereof in association with a suitable diluent or pharmaceutically acceptable carrier.
17. The use of a pharmaceutical composition for use in treating ischemia damage in tissue, the use comprising administering an effective non-toxic amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, ester, fragments and units of hyaluronic acid for treating ischemia damage in tissue, in association with a suitable diluent or pharmaceutically acceptable carrier.
18. The use of a pharmaceutical composition for treating ischemia damage in tissue comprising an effective non-toxic amount of hyaluronic acid and/or salts thereof for treating ischemia damage in tissue in association with a suitable diluent or pharmaceutically acceptable carrier.
19. The use of claim 17 wherein the amount of the form of hyaluronic acid administered is between about 300 mg and about 7 grams/70 kg person per day.
20. The use of claim 18 wherein the amount of hyaluronic acid or salt thereof administered is between about 300 mg and about 7 grams/70 kg person per day.
21. The use of the pharmaceutical composition of claim 18 or 20 wherein the tissue is selected from the internal organs.
22. The use of the pharmaceutical composition of claim 18 or 20 wherein the tissue is the liver.
23. The use of the pharmaceutical composition of claim 18 or 20 wherein the tissue is the kidneys.
24. The use of the pharmaceutical composition of claim 18 or 20 wherein the tissue is the heart.
25. The use of the pharmaceutical composition of claim 18 or 20 wherein the composition is used for treating or preventing ischemia damage in tissue during transplantation.
26. The use of the pharmaceutical composition of claim 18 or 20 wherein the composition is used for treating or preventing ischemia damage in tissue during transplantation of internal organs.
27. The use of the pharmaceutical composition of claim 18 or 20 wherein the composition is used for treating or preventing ischemia damage in tissue during transplantation of the liver.
28. The use of the pharmaceutical composition of claim 18 or 20 wherein the composition is used for treating or preventing ischemia damage in tissue during transplantation of the kidney or kidneys.
29. The use of the pharmaceutical composition of claim 18 or 20 wherein the composition is used for treating or preventing ischemia damage in tissue during transplantation of the heart.
30. The use of a formulation for the medical treatment of reducing Alanine Aminotransferase enzyme production by a liver when damaged or experiencing ischemia comprising administering a formulation comprising an effective non-toxic amount of hyaluronic acid and/or salts thereof in association with a suitable diluent or pharmaceutically acceptable carrier to the liver.
31. The use of claim 30 wherein the amount of hyaluronic acid and/or salts thereof is from about 300 mg to about 7 grams/70 kg person per day.
32. The formulation of claim 16 wherein the amount of hyaluronic acid and/or salts thereof is from between about 300 mg to about 7 grams.
33. The pharmaceutical composition of claim 2 for use in treating ischemia damage in the lungs.
34. The use of the pharmaceutical composition of claim 18 or 20 wherein the tissue is the lungs.
35. The use of the pharmaceutical composition of claim 18 or 20 wherein the composition is used for treating or preventing ischemia damage in tissue during the transplantation of the lungs.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002061567A CA2061567C (en) | 1992-02-20 | 1992-02-20 | Use of hyaluronic acid to repair ischemia reperfusion damage |
| SG1996002901A SG49654A1 (en) | 1992-02-20 | 1993-02-19 | The use of hyaluronic acid to repair ischemia reperfusion damage |
| EP93301230A EP0557118A1 (en) | 1992-02-20 | 1993-02-19 | The use of hyaluronic acid to repair ischemia reperfusion damage |
| US08/200,309 US5674857A (en) | 1992-02-20 | 1994-02-23 | Use of hyaluronic acid to repair ischemia reperfusion damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002061567A CA2061567C (en) | 1992-02-20 | 1992-02-20 | Use of hyaluronic acid to repair ischemia reperfusion damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2061567A1 CA2061567A1 (en) | 1993-08-21 |
| CA2061567C true CA2061567C (en) | 1998-02-03 |
Family
ID=4149301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002061567A Expired - Lifetime CA2061567C (en) | 1992-02-20 | 1992-02-20 | Use of hyaluronic acid to repair ischemia reperfusion damage |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US5674857A (en) |
| EP (1) | EP0557118A1 (en) |
| CA (1) | CA2061567C (en) |
| SG (1) | SG49654A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834444A (en) * | 1991-07-03 | 1998-11-10 | Hyal Pharmaceutical Corporation | Hyaluronic acid and salts thereof inhibit arterial restenosis |
| CA2130762C (en) * | 1994-08-24 | 1999-07-06 | Eva Anne Turley | Treatment of disease and conditions associated with macrophage infiltration |
| US5585361A (en) * | 1994-06-07 | 1996-12-17 | Genzyme Corporation | Methods for the inhibition of platelet adherence and aggregation |
| US5591724A (en) * | 1995-02-14 | 1997-01-07 | Bioniche Inc. | Method for treating the urinary bladder and associated structures using hyaluronic acid |
| JP4627580B2 (en) * | 2000-06-08 | 2011-02-09 | 生化学工業株式会社 | Liver disease treatment |
| WO2002035929A1 (en) * | 2000-11-03 | 2002-05-10 | Vitrolife Ab | Evaluation and preservation solution |
| JP4537057B2 (en) | 2001-08-14 | 2010-09-01 | テルアビブ・ユニバーシティ・フューチャー・テクノロジー・デベロップメント・エルピー | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and treatment |
| US9241735B2 (en) | 2003-12-05 | 2016-01-26 | Onset Medical Corporation | Expandable percutaneous sheath |
| CA2560200A1 (en) * | 2004-03-17 | 2005-09-22 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Cd44-targeting for reducing/preventing ischemia-reperfusion-injury |
| US20060135962A1 (en) | 2004-09-09 | 2006-06-22 | Kick George F | Expandable trans-septal sheath |
| US7892203B2 (en) | 2004-09-09 | 2011-02-22 | Onset Medical Corporation | Expandable transluminal sheath |
| US8337518B2 (en) | 2006-12-20 | 2012-12-25 | Onset Medical Corporation | Expandable trans-septal sheath |
| GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
| JP6091415B2 (en) * | 2010-10-07 | 2017-03-08 | ナショナル チェン クン ユニバーシティー | Use of hyaluronan to promote ischemic limb blood flow in diabetes |
| IN2014MN01886A (en) | 2012-04-18 | 2015-07-10 | Univ Ramot | |
| EP3160448A4 (en) | 2014-06-26 | 2018-11-14 | Ramot at Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
| CN112972490B (en) * | 2021-03-04 | 2022-02-18 | 中国人民解放军军事科学院军事医学研究院 | Application of hyaluronic acid in preparing medicine for preventing or treating iron death related diseases |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4303676A (en) * | 1980-03-21 | 1981-12-01 | Balazs Endre A | Hyaluronate based compositions and cosmetic formulations containing same |
| US4684627A (en) * | 1981-09-08 | 1987-08-04 | Leveen Harry H | Treatment of cancer with phlorizin and its derivatives |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| IT1229075B (en) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Topical compsn. contg. hyaluronic acid deriv. as vehicle |
| AU555747B2 (en) * | 1983-08-09 | 1986-10-09 | Cilco Inc. | Chondroitin sulfate and sodium hyaluronate composition |
| IN163192B (en) * | 1983-10-11 | 1988-08-20 | Fidia Spa | |
| NO161573C (en) * | 1983-11-25 | 1989-08-30 | Miles Inc | PROCEDURE FOR THE PREPARATION OF HYALURONIC ACID. |
| CA1295796C (en) * | 1984-03-27 | 1992-02-18 | Conrad Whyne | Biodegradable matrix and methods for producing same |
| JPS6117A (en) * | 1984-06-11 | 1986-01-06 | Seikagaku Kogyo Co Ltd | Mucopolysaccharide-type cancer-metastatis suppressing agent |
| US4711780A (en) * | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
| US4735902A (en) * | 1984-10-23 | 1988-04-05 | Matti Siren | Stabilized composition containing inositoltriphosphate |
| US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| EP0187703B1 (en) * | 1985-01-11 | 1992-08-05 | Teijin Limited | Sustained release preparation |
| US4784990A (en) * | 1985-01-18 | 1988-11-15 | Bio-Technology General Corporation | High molecular weight sodium hyaluronate |
| US4719201A (en) * | 1985-02-07 | 1988-01-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia |
| US4713448A (en) * | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
| SE8501723L (en) * | 1985-04-09 | 1986-10-10 | Pharmacia Ab | PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION |
| US4725585A (en) * | 1985-04-26 | 1988-02-16 | Pharmacia Ab | Method of enhancing the host defense |
| EP0207638B1 (en) * | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
| US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| FR2584606A1 (en) * | 1985-07-12 | 1987-01-16 | Dropic | USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE |
| IN166447B (en) * | 1985-11-27 | 1990-05-12 | Ethicon Inc | |
| EP0224987B1 (en) * | 1985-11-29 | 1992-04-15 | Biomatrix, Inc. | Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same |
| JP2604135B2 (en) * | 1986-02-28 | 1997-04-30 | ライオン株式会社 | Oral bone disease treatment |
| EP0240098A3 (en) * | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
| EP0244178A3 (en) * | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
| US4808576A (en) * | 1986-04-28 | 1989-02-28 | Mobay Corporation | Remote administration of hyaluronic acid to mammals |
| IT1213301B (en) * | 1986-07-14 | 1989-12-20 | Zambon Spa | COMPOSITIONS FOR THE TREATMENT OF SYNDROMES FROM ISCHEMIA AND REPERFUSION |
| IT1198449B (en) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID |
| ZA878877B (en) * | 1986-11-29 | 1988-05-24 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of diseases caused by viruses |
| GB8706052D0 (en) * | 1987-03-13 | 1987-04-15 | Medical Research Int | Therapeutic compositions |
| ATE129254T1 (en) * | 1987-03-19 | 1995-11-15 | Arthropharm Pty Ltd | ANTI-INFLAMMATORY AGENTS AND COMPOSITIONS. |
| EP0285357A3 (en) * | 1987-03-31 | 1989-10-25 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Control of retroviruses |
| US4795741A (en) * | 1987-05-06 | 1989-01-03 | Biomatrix, Inc. | Compositions for therapeutic percutaneous embolization and the use thereof |
| GB8713747D0 (en) * | 1987-06-12 | 1987-07-15 | Unilever Plc | Skin treatment composition |
| US4931460A (en) * | 1987-09-17 | 1990-06-05 | E. R. Squibb & Sons, Inc. | Post-ischemic myocardial dysfunction using thromboxane A2 antagonists |
| NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| US4968671A (en) * | 1987-11-26 | 1990-11-06 | Yamanouchi Pharmaceutical Co., Ltd. | Therapeutic agents for ischemic heart diseases |
| US4988515A (en) * | 1988-01-28 | 1991-01-29 | The Regents Of The Univ. Of Calif. | Cardioplegic solution |
| DK505588D0 (en) * | 1988-02-26 | 1988-09-09 | Jesper Hamburger | MEDIUM AND USE OF SAME |
| JPH01287041A (en) * | 1988-05-13 | 1989-11-17 | Rooman Kogyo:Kk | Sustained release preparation |
| IT1219587B (en) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
| US5057494A (en) * | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| US5095037B1 (en) * | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
| WO1991015215A1 (en) * | 1990-03-30 | 1991-10-17 | Biomedical Frontiers, Inc. | Fluid resuscitation |
| US5099012A (en) * | 1990-12-11 | 1992-03-24 | Eastman Kodak Company | Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury |
| US5095027A (en) * | 1991-02-28 | 1992-03-10 | Clintec Nutrition Co. | Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid |
| DE19538814C2 (en) * | 1995-10-18 | 1998-07-09 | Obermaier Geb Ohg | Foot massager |
-
1992
- 1992-02-20 CA CA002061567A patent/CA2061567C/en not_active Expired - Lifetime
-
1993
- 1993-02-19 EP EP93301230A patent/EP0557118A1/en not_active Ceased
- 1993-02-19 SG SG1996002901A patent/SG49654A1/en unknown
-
1994
- 1994-02-23 US US08/200,309 patent/US5674857A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5674857A (en) | 1997-10-07 |
| EP0557118A1 (en) | 1993-08-25 |
| SG49654A1 (en) | 1998-06-15 |
| CA2061567A1 (en) | 1993-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2061567C (en) | Use of hyaluronic acid to repair ischemia reperfusion damage | |
| US5614506A (en) | Use of hyaluronic acid and forms to prevent arterial restenosis | |
| EP2540284B1 (en) | Compositions and methods for stabilized polysaccharide formulations | |
| CA2122519C (en) | Cancer treatment and metastasis prevention | |
| US6537978B1 (en) | Oral administration of effective amounts of forms of hyaluronic acid | |
| US20070054878A1 (en) | Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis | |
| WO1996006622A1 (en) | Hyaluronic acid and derivatives for modulation of cellular activity | |
| AU694113B2 (en) | Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID | |
| CA2130762C (en) | Treatment of disease and conditions associated with macrophage infiltration | |
| US5817642A (en) | Clearing of atherosclerosis | |
| US5767106A (en) | Treatment of disease and conditions associated with macrophage infiltration | |
| CA2208924A1 (en) | Sparing paclitaxel by the use of hyaluronan | |
| EP0874624B1 (en) | Hyaluronic acid receptors binding agents and their use for treating tumors or restenosis | |
| AU727001B2 (en) | Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS) | |
| JP2667441B2 (en) | Vascular endothelial cell growth inhibitor | |
| US5817644A (en) | Targeting of dosages of medicine and therapeutic agents | |
| EP0758246A1 (en) | Pharmaceutical composition comprising hyaluronic acid for the clearing of arteriosclerosis | |
| CA2164260C (en) | Targeting of dosages of medicines and therapeutic agents | |
| CA2167044C (en) | Oral administration of effective amounts of forms of hyaluronic acid | |
| CA2131130A1 (en) | Modulation of cellular activity | |
| CA2121454A1 (en) | Inhibition, control and regression of angiogenesis | |
| CA2193921A1 (en) | Oral administration of effective amounts of forms of hyaluronic acid according to various standards | |
| CA2166154A1 (en) | Binding agents and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |